Captrust Financial Advisors acquired a new stake in bluebird bio, Inc. (NASDAQ:BLUE) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 3,237 shares of the biotechnology company’s stock, valued at approximately $340,000.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Bank of Montreal Can increased its holdings in shares of bluebird bio by 118.9% in the 2nd quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock valued at $176,000 after acquiring an additional 911 shares during the last quarter. Turner Investments LLC acquired a new stake in shares of bluebird bio in the 2nd quarter valued at about $184,000. SG Americas Securities LLC boosted its position in shares of bluebird bio by 17.9% in the 2nd quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 295 shares during the period. Affinity Investment Advisors LLC acquired a new stake in shares of bluebird bio in the 2nd quarter valued at about $246,000. Finally, Berkeley Capital Partners LLC acquired a new stake in shares of bluebird bio in the 1st quarter valued at about $282,000.
In other bluebird bio news, Director Daniel Lynch sold 4,000 shares of the company’s stock in a transaction that occurred on Friday, June 23rd. The stock was sold at an average price of $109.09, for a total value of $436,360.00. Following the completion of the sale, the director now directly owns 4,808 shares in the company, valued at $524,504.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David Davidson sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 5th. The stock was sold at an average price of $105.28, for a total value of $526,400.00. Following the completion of the sale, the insider now owns 22,177 shares of the company’s stock, valued at $2,334,794.56. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 153,248 shares of company stock valued at $17,708,425. Insiders own 3.90% of the company’s stock.
BLUE has been the subject of a number of research analyst reports. Cantor Fitzgerald set a $37.00 target price on bluebird bio and gave the company a “sell” rating in a research report on Monday, June 5th. BTIG Research cut bluebird bio from a “buy” rating to a “neutral” rating and upped their target price for the company from $37.05 to $108.25 in a research report on Friday, June 30th. Jefferies Group LLC reissued a “buy” rating on shares of bluebird bio in a research report on Thursday, July 6th. Zacks Investment Research raised bluebird bio from a “hold” rating to a “buy” rating and set a $118.00 target price for the company in a research report on Tuesday, July 4th. Finally, Cowen and Company reissued an “outperform” rating on shares of bluebird bio in a research report on Thursday, August 31st. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $107.86.
bluebird bio, Inc. (NASDAQ BLUE) traded down 0.19% during mid-day trading on Friday, hitting $131.60. The stock had a trading volume of 306,526 shares. The company has a 50-day moving average of $105.28 and a 200-day moving average of $96.03. bluebird bio, Inc. has a 12-month low of $37.05 and a 12-month high of $136.85. The stock’s market cap is $6.00 billion.
bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.66) by ($0.07). The business had revenue of $16.70 million for the quarter, compared to analyst estimates of $6.29 million. bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The business’s quarterly revenue was up 977.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.59) earnings per share. On average, analysts anticipate that bluebird bio, Inc. will post ($6.84) earnings per share for the current fiscal year.
bluebird bio Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio, Inc. (NASDAQ:BLUE).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.